Octocrylene

Octocrylene

SCHEMBL1655403

CCCCC(CC)COC(=O)/C=C/c1ccc(OC)cc1.CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.71
ALDH1A1 P00352 2/20 0.71
MAPK1 P28482 1/20 0.71
TDP1 Q9NUW8 3/20 0.69
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TAS1R3 Q7RTX0 2/20 0.43
TAS1R1 Q7RTX1 2/20 0.43
CYP3A4 P08684 2/20 0.41
BCHE P06276 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
CA2 P00918 1/20 0.40
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amiloxate SCHEMBL26646558 0.93 ALDH1A1 (0.64) LMNAALDH1A1MAPK1TDP1MEN1
Octocrylene SCHEMBL28166919 0.93 LMNA (0.64) LMNAALDH1A1MAPK1TDP1MEN1
Amiloxate SCHEMBL26646557 0.93 ALDH1A1 (0.64) LMNAALDH1A1MAPK1TDP1MEN1
SCHEMBL469376 0.89 ALDH1A1 (0.86) LMNAALDH1A1MAPK1TDP1CYP3A4
SCHEMBL21908164 0.89 ALDH1A1 (0.86) LMNAALDH1A1MAPK1TDP1CYP3A4
SCHEMBL16762811 0.89 ALDH1A1 (0.86) LMNAALDH1A1MAPK1TDP1CYP3A4
SCHEMBL346933 0.89 ALDH1A1 (0.86) LMNAALDH1A1MAPK1TDP1CYP3A4
Octinoxate SCHEMBL1408448 0.86 TDP1 (0.84) LMNAALDH1A1MAPK1TDP1MEN1
Octocrylene SCHEMBL1769135 0.84 ALDH1A1 (1.00) LMNAALDH1A1MAPK1TDP1MEN1
Octocrylene SCHEMBL16483 0.84 ALDH1A1 (1.00) LMNAALDH1A1MAPK1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202735-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS TPC-API LLC 2022-06-30 US disclosed
EP-3345594-B1 SOLUBILIZED FLAVONOID COMPOSITION TECH INVESTMENTS LC (US) 2021-11-17 EP disclosed
US-11135177-B2 Methods of making and using compositions comprising flavonoids VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. (US) 2021-10-05 US disclosed
US-20210000958-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. 2021-01-07 US disclosed
EP-3345594-A1 SOLUBILIZED FLAVONOID COMPOSITION Vizuri Health Sciences LLC (US) 2018-07-11 EP disclosed
US-9889098-B2 Methods of making and using compositions comprising flavonoids VIZURI HEALTH SCIENCES LLC (US) 2018-02-13 US disclosed
US-20180008553-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS TPC-API LLC 2018-01-11 US disclosed
EP-2629763-B1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS VIZURI HEALTH SCIENCES LLC (US) 2017-12-06 EP disclosed
US-20170296668-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. 2017-10-19 US disclosed
US-9730953-B2 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound VIZURI HEALTH SCIENCES LLC (US) 2017-08-15 US disclosed
EP-2701670-A1 CLEAR WET SPRAYS AND GELS Isp Investments Inc. (US) 2014-03-05 EP disclosed
US-8637569-B2 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds API GENESIS, LLC (US) 2014-01-28 US disclosed
EP-2629763-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS API Genesis, LLC (US) 2013-08-28 EP disclosed
WO-2012149355-A1 CLEAR WET SPRAYS AND GELS ISP INVESTMENTS INC. (US) 2012-11-01 WO disclosed
EP-2490679-A2 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS API Genesis, LLC (US) 2012-08-29 EP disclosed
US-20120213842-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS TPC-API LLC 2012-08-23 US disclosed
WO-2012078961-A1 COMPOSITIONS COMPRISING STABILIZED KETO-ENOL UV ABSORBERS ISP INVESTMENT INS. (US) 2012-06-14 WO disclosed
WO-2011049629-A9 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS API GENESIS, LLC (US) 2012-05-18 WO disclosed
WO-2012054090-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS API GENESIS, LLC (US) 2012-04-26 WO disclosed
WO-2011049629-A2 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS API GENESIS, LLC (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11135177-B2 Methods of making and using compositions comprising flavonoids F3, C5, CYP51A1 LMNA 2475/4885ALDH1A1 2963/4885MAPK1 2120/4885
US-20220202735-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS F3, C5, CYP51A1 LMNA 2475/4885ALDH1A1 2963/4885MAPK1 2120/4885
US-20210000958-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND ABCG2, CYP2F1, LSS LMNA 3422/4885ALDH1A1 1920/4885MAPK1 2589/4885
US-20180008553-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS F3, C5, CYP51A1 LMNA 2475/4885ALDH1A1 2963/4885MAPK1 2120/4885
US-20170296668-A1 METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND ABCG2, CYP2F1, LSS LMNA 3422/4885ALDH1A1 1920/4885MAPK1 2589/4885
US-20120213842-A1 METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS F3, C5, CYP51A1 LMNA 2475/4885ALDH1A1 2963/4885MAPK1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.